Processa Pharmaceuticals (PCSA) Share-based Compensation (2012 - 2026)

Processa Pharmaceuticals (PCSA) has reported Share-based Compensation for 14 consecutive years, with $136372.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation fell 61.85% year-over-year to $136372.0; the trailing twelve-month figure through Jun 2026 stood at $136372.0 (down 61.85% YoY), and the FY2025 full-year result was $857550.0, up 36.22% from the prior year.
• Share-based Compensation steadied at $136372.0 in Q2 2026 per PCSA's latest filing, from $136372.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $10.4 million in Q3 2025 and bottomed at $123541.0 in Q4 2025.
• Historically, Share-based Compensation has averaged $1.7 million across 5 years, with a median of $781734.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation sank 87.98% in 2024, then jumped 2828.8% in 2025.
• Over 5 years, Share-based Compensation stood at $2.9 million in 2022, then slumped by 63.39% to $1.1 million in 2023, then slumped by 85.38% to $155048.0 in 2024, then declined by 20.32% to $123541.0 in 2025, then rose by 10.39% to $136372.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $136372.0, $136372.0, and $123541.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.